Jetrea, developed by ThromboGenics, offers ?major added value? for the treatment of vitreomacula traction and macular hole, claims the German Institute for Quality and Efficiency in Health Care (IQWiG).
Jetrea, developed by ThromboGenics, offers “major added value” for the treatment of vitreomacula traction and macular hole, claims the German Institute for Quality and Efficiency in Health Care (IQWiG).
Jetrea contains the active substance ocriplasmin and is administered through one intravitreal injection in adults with VMT and macular hole of a diameter less than or equal to 400 microns.
The treatment breaks down the protein fibres, which cause abnormal traction between the vitreous and the macula that causes VMT. It then releases traction and helps to complete vitreous detachment from the macula.
Dr Patrick De Haes, CEO of ThromboGenics, stated, “IQWiG’s assessment confirming the significant additional benefits of Jetrea for VMT validates the importance of our novel drug in treating patients with this major sight-threatening disease.”
“For the first time, patients can be treated at an earlier stage of their disease, rather than having to watch and wait until their symptoms worsen,” continued Dr De Haes. “We, and our partner Alcon, look forward to working with G-BA to ensure that the positive benefits shown by Jetrea are reflected in its final guidance.”